Roche concerned about 'neglect' of patent rules in India, but stays committed
This article was originally published in Scrip
Executive Summary
Days after a second patent-related setback in India in recent times, Roche says that it is concerned about a "policy of neglect" for patent rules that would inhibit future research, though the Swiss firm stressed that it continues to stay "committed" to its business in India.
You may also be interested in...
Seretide Settlement Lifts Glenmark In Europe
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Novartis Logs Into India With Digital Innovation Hub
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Seretide Settlement To Lift Glenmark’s Europe Business
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Need a specific report? 1000+ reports available
Buy Reports